GenSight Biologics Secures €1 Million Funding from Shareholders

GenSight Biologics has successfully raised €1 million through a fundraising initiative backed by existing shareholders, Heights Capital and Invus. The biopharma company, focused on gene therapies for retinal and central nervous system disorders, will use the proceeds to support ongoing operations and the RECOVER Phase III trial. The net proceeds are estimated at €0.95 million.

This fundraising mirrors a similar financing structure undertaken in March 2026, involving shares and warrants. GenSight aims to secure additional financing by November 2026 to meet funding needs up to €2 million. The company’s CFO, Jan Eryk Umiastowski, thanked shareholders for their support, highlighting ongoing cash generation from early access programs and successful manufacturing process transfers.

The issuance bypasses the need for prospectus approval by the French Financial Market Authority. Trading of the Offered Shares is set to commence on Euronext Paris by mid-October 2026.